Fingolimod recommended by NICE as an option for MS

NICE has approved fingolimod (Gilenya), the first oral treatment for patients with highly active relapsing-remitting multiple sclerosis.

Gilenya (fingolimod) was rejected by the SMC earlier this year
Gilenya (fingolimod) was rejected by the SMC earlier this year
Fingolimod (Gilenya), the first licensed sphingosine 1-phosphate receptor modulator, may be prescribed on the NHS for patients with an unchanged or increased relapse rate or ongoing severe relapses compared with the previous year despite treatment with interferon beta. However, the manufacturer must provide fingolimod with the discount agreed as part of the patient access scheme.

Safety concerns

The MHRA recently published updated monitoring advice for fingolimod following reports of sudden cardiac death after the initial dose.

Guidance summary

NICE guidance on fingolimod

Further information

View Gilenya drug record

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

MIMS Product Slides

Product overviews prepared by the MIMS team, in a handy slide format.

Click here

Slides are initiated, funded & reviewed by the companies specified.

MIMS app

Access the full drug database and quick-reference tables on the go

Find out more